Though simple loss of GR has been documented in lymphoblasts from late-stage resistant ALL, and from some lymphomas, this mechanism does not seem to explain the majority of clinical resistance to GCs [20,21,53]. This evidence concerns the gene NR3C1 and acute lymphoblastic leukemia.